Trial Details

COMPLETED
Basic Information
Clinical ID c2909
Identifier NCT02798991
Trial Title A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Irritable Bowel Syndrome
Interventions DRUG: GSK3179106|DRUG: Matched Placebo
Participant Information
Sponsor GlaxoSmithKline
City South Australia
Country/Region Australia
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE1
Time Information
Start Date 2016-06
Primary Completion Date 2016-11
Completion Date 2016-11